Tag: Pharmaceuticals

In the most recent of a string of announcements ahead of the holiday season, Centers for Medicare & Medicaid Services (CMS) has unveiled a new...

The French pharma giant, Sanofi, has started a $15.50 per share cash tender offer when it comes to Emeryville, California-based vaccine developer Dynavax, which...

On December 22, 2025, the news has been confirmed of Samsung Biologics to Buy US Drug Plant which is going to be its first...

President Donald Trump on December 19, 2025, said that his administration has reached agreements with nine additional pharmaceutical companies, therefore extending a campaign that...

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

The era of "gut feeling" in pharmaceutical portfolio management is ending. This article explores how advanced analytics, machine learning, and predictive modeling are revolutionizing project prioritization. It details the shift to Monte Carlo simulations, integrated data lakes, and AI-driven decision support, enabling companies to objectively rank programs and optimize R&D return on investment.